ArticleIn vivo (Athens, Greece)
Impact of Thyroid Dose on Radiation-induced Hypothyroidism in Early Glottic Cancer Patients Undergoing Volumetric Modulated Arc Therapy.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Feasibility of Lower Neck Sparing in Postoperative Radiotherapy for Parotid Gland Cancer.In vivo (Athens, Greece)Article
- Comparison of Survival Outcomes and Toxicities Between Volumetric-modulated Arc Therapy and Conventional Radiotherapy in Early Glottic Cancer.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimTo evaluate the incidence of radiation-induced hypothyroidism (RIHT) and its association with thyroid dose in patients undergoing volumetric modulated arc therapy (VMAT) for early glottic cancer. PATIENTS AND
methodsWe retrospectively reviewed 23 patients with early glottic cancer who received VMAT between 2018 and 2023. All included patients had normal baseline thyroid function tests. RIHT was defined as an increase in thyroid-stimulating hormone levels with or without a decrease in free-T4 or T3 levels. Dose-volume parameters (DVPs) of the thyroid gland, including mean dose and the relative thyroid volume receiving at least 10-60 Gy (V
resultsThe median follow-up time was 36.4 months, during which all patients survived. The 1-year and 3-year local failure-free survival rates were 91.3% and 82.4%, respectively. The median mean dose was 25.2 Gy. RIHT developed in five patients (21.7%), with a median onset time of 16.7 months after VMAT. Among them, one patient received thyroid hormone therapy. Among the DVPs, V
conclusionA considerable proportion of patients developed RIHT after VMAT for early glottic cancer. The thyroid gland should be recognized as an important organ at risk. For VMAT planning, V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.